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Background: According to the American Cancer Society, over 68,000 men and women will die 
from prostate and breast cancer in this year alone. Prostate, breast and other cancers have 
been shown to express the BB2 receptor.  For the past decade the Hoffman laboratory has 
been synthesizing radiopharmaceutical conjugates based on the Bombesin (BBN) peptide (Gln-
Trp-Ala-Val-Gly-His-Leu-Met-NH2) that target the BB2 receptor for diagnosis and treatment of 
cancer.  The radioconjugates are composed of a bombesin targeting vector, linking group, 
chelation moiety and a radioactive metal. One focus of our group is to investigate the efficacy of 
new Bombesin Targeting Vectors (BTV) which are derivatives of the BBN peptide. In the sixth 
position of the BTV is a D-phenylalanine amino acid.  Our hypothesis is that the D-
phenylalanine is responsible for significantly reducing kidney retention.  Reduction of kidney 
retention is crucial for clinical radiotherapeutic applications because the kidney is often the dose 
limiting organ.  In order to understand the structure function relationship of the D-phenylalanine 
in the BTV targeting vectors, we synthesized and evaluated the BTV peptide with the L-
phenylalanine in the sixth position to determine what effect the stereochemistry has upon the in 
vitro receptor binding and in vivo pharmacokinetic properties of the peptide.  Methods: The 
peptides were synthesized using solid phase peptide synthesis, purified using RP-HPLC, and 
characterized using electrospray mass spectrometry.  Radiolabeling of the peptides was 
performed using 111InCl3.  In vitro cell binding assays and internalization and efflux studies were 
performed using the PC-3 human cancer cell line. In vivo pharmacokinetic studies were 
performed using CF-1 mice. Micro-SPECT (single photon emission computed tomography) 
imaging studies were performed in PC-3 SCID mice. Results: In vivo pharmacokinetic studies 
at 15 min post-injection gave 39.85 ± 5.07 %ID/g in the BB2 receptor expressing mouse 
pancreas for the L-Phe-BTV radioconjugate compared to 10.30 ± 0.34 for the D-Phe-BTV.  
Surprisingly, the kidney clearance for both radioconjugates was statistically identical.  
Conclusion: Incorporation of the L-Phe instead of the D-Phe into the sixth position of the BTV 
had no statistically significant effect upon the renal clearance of the radioconjugate.  However, 
the change in stereochemistry from the L to the D-form had significant effects upon the in vivo 
uptake and retention of the radioconjugate.  Further investigations will be conducted to 
understand the mechanism responsible for the difference in uptake and retention of the two 
Bombesin radioconjugates. 
